This trial showed Enstilar to be superior to Daivobet ointment, achieving both primary and secondary endpoints. The Center for Drug Evaluation (CDE) in China will now validate and fully evaluate ...

This is another substantial milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in ...

This is another substantial clinical development milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval ...